OptiBiotix Health PLC License agreement with Tata Chemicals (8588Q)
23 Outubro 2023 - 3:00AM
UK Regulatory
TIDMOPTI
RNS Number : 8588Q
OptiBiotix Health PLC
23 October 2023
Opti B i otix Health plc
( "Opti Bi o t ix" or the "Company")
License agreement with Tata Chemicals
OptiBi otix Health p lc (AI M : OPTI), a life sciences busi ness
d e vel o ping co m p o u n ds to tack le o besit y, high choleste
r ol, diabetes and skincare, announces that it has reached an
agreement with Tata Chemicals Limited ("Tata Chemicals") to
incorporate its proprietary Fossence (R) into SlimBiome (R) and
LeanBiome (R) for the Indian market.
The agreement incorporates Tata's Fossence (R) , a proprietary
short chain fructo-oligosaccharide ("FOS") into OptiBiotix's
SlimBiome (R) and LeanBiome (R) products for the Indian market.
Fossence (R) will be a direct replacement for the FOS used in
SlimBiome (R) in other markets and brings scientific substantiation
of health benefits shown by FOS in the Indian market (see Explore -
Brochures, Whitepapers, Concept Notes & More | Tata NQ ). Tata
Chemicals have approved the use of the Fossence (R) logo on
products containing SlimBiome(R) in India bringing a branded
ingredient from a well-known and trusted source to the attention of
Indian consumers.
Tata Chemicals is a global science company active in industrial
chemicals, food and nutrition (Tata NQ), and agriculture listed on
the Indian stock Exchange. It is part of the Tata Group which
employs over one million people with annual revenues in 2022 of
$300billion.
S tep hen O'Ha r a, CEO of O pti B i oti x, c o mmented: "We are
pleased to report this agreement with Tata Chemicals which creates
the opportunity to bring products containing Tatas proprietary
Fossence (R) in SlimBiome (R) and LeanBiome (R) to the Indian
market. Tata Chemicals is one of India's leading suppliers of food
ingredients with many well-known and respected brands. Fossence's
(R) established health benefits with Indian consumers and its
trusted brand combined with SlimBiome's (R) strong science,
clinical studies, and excellent customer reviews will help reduce
hunger and food cravings to support the weight management efforts
of India's 135 million obese men and women ."
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Neil Davidson, Chairman Contact via Walbrook below
Stephen O'Hara, Chief Executive
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
Peterhouse Capital Limited (Broker) Tel: 020 7220 9797
Duncan Vasey / Lucy Williams
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D programme working with
leading academics in the development of microbial strains,
compounds, and formulations which are used as active ingredients
and supplements. More than twenty international food and healthcare
supplement companies have signed agreements with OptiBiotix to
incorporate their human microbiome modulators into a wide range of
food products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFLFLEIRLIFIV
(END) Dow Jones Newswires
October 23, 2023 02:00 ET (06:00 GMT)
OptiBiotix Health (AQSE:OPTI.GB)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
OptiBiotix Health (AQSE:OPTI.GB)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
